The FDA is working in close collaboration with global regulatory partners to evaluate the controls in place and publish guidance on preventing unacceptable levels of nitrosamine in drugs.
[Breast Cancer: Targets and Therapy] A population-based case-control study explored whether the association between mammographic density as a risk factor for breast cancer differs across breast cancer tumor subtypes.
The FDA has concluded that the use of entacapone to treat Parkinson disease (PD) does not increase the risk of developing prostate cancer.
Findings from prospective cohort study of sisters or half-sisters of women diagnosed with breast cancer.
Increased incidences found for lymphoma, lung cancer (in male patients), and cervical cancer.
FDA requested recall to protect women from breast implant-associated anaplastic large cell lymphoma.
Prevalence highest for those working in industries with outdoor workplaces unprotected by smoke-free laws.
From 2011 to 2017, quit attempts increased in four states, decreased in two states.
Allergan is recalling BIOCELL textured breast implants and tissue expanders due to the potential risk for breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). The move to recall was based on an analysis of medical device reports submitted to the Food and Drug Administration (FDA) related to BIA-ALCL and BIA-ALCL-related deaths associated with these devices. “Once…
Cancer risk up for MS patients versus non-MS controls, especially in respiratory, urinary, CNS organs
